Drug Trial Radar · NCT06433609
Study of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast Cancer
Last checked: Nov 19, 2026Latest source record: Jul 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
113
Planned (sponsor's estimate)
Start
Aug 5, 2024
Primary completion
Mar 2027
Study completion Nov 2027
Sponsor
- Lead sponsor
- Beijing GoBroad HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 30, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Our study is aimed to evaluate the efficacy and safety of novel ADCs named SHR-A1811, SHR-A1921 and SHR-A2102 combined with adebrelimab in HER2-negative advanced breast cancer.
Conditions
- Advanced Breast Cancer
Interventions
SHR-A1811Drug
Via intravenous infusion
SHR-A1921Drug
Via intravenous infusion
AdebrelimabDrug
Via intravenous infusion
SHR-A2102Drug
Via intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- ORR (objective response rate) by investigatorTime frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3.5 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing GoBroad Hospital
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.